載脂蛋白B(APOB)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法)
CLIA Kit for Apolipoprotein B (APOB)
Apo-B; FLDB; Apo B-100; Apo B-48
- 編號(hào)SCC003Hu
- 物種Homo sapiens (Human,人) 相同的名稱(chēng),不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)2h, 40min
- 檢測(cè)范圍6.86-5,000ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于2.84ng/mL.
- 樣本類(lèi)型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 3528 ¥ 5040 ¥ 22680 ¥ 42840 ¥ 352800
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
特異性
本試劑盒用于檢測(cè)載脂蛋白B(APOB),經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的載脂蛋白B(APOB)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 90-99 | 96 |
EDTA plasma(n=5) | 83-101 | 92 |
heparin plasma(n=5) | 93-104 | 98 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線(xiàn)性
在定值血清及血漿樣本內(nèi)加入適量的載脂蛋白B(APOB),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線(xiàn)性范圍即為稀釋后樣本中載脂蛋白B(APOB)含量的測(cè)定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 98-105% | 97-104% | 79-96% | 99-105% |
EDTA plasma(n=5) | 79-102% | 79-101% | 80-99% | 98-105% |
heparin plasma(n=5) | 79-101% | 95-103% | 87-97% | 85-97% |
穩(wěn)定性
經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品及樣本)100µL,37°C孵育1小時(shí);
3. 吸棄,加檢測(cè)溶液A100μL,37°C孵育1小時(shí);
4. 洗板3次;
5. 加檢測(cè)溶液B100µL,37°C孵育30分鐘;
6. 洗板5次;
7. 加底物100µL,37°C孵育10分鐘;
8. 讀數(shù)。
實(shí)驗(yàn)原理
將載脂蛋白B(APOB)抗體包被于96孔微孔板中,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本,其中的載脂蛋白B(APOB)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的載脂蛋白B(APOB)抗體,將未結(jié)合的生物素化抗體洗凈后,加入HRP標(biāo)記的親和素,再次徹底洗滌后加入底物。加入底物后會(huì)產(chǎn)生輝光型光信號(hào)。發(fā)射光強(qiáng)度和樣品中的載脂蛋白B(APOB)呈正相關(guān)。用化學(xué)發(fā)光儀測(cè)定相對(duì)光單位(RLU),計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
NPC003Hu01 | 載脂蛋白B(APOB)天然蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPC003Hu02 | 載脂蛋白B(APOB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPC003Hu01 | 載脂蛋白B(APOB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAC003Hu02 | 載脂蛋白B(APOB)多克隆抗體 | WB; IHC; ICC; IP. |
PAC003Hu01 | 載脂蛋白B(APOB)多克隆抗體 | WB; IHC; ICC; IP. |
LAC003Hu81 | 載脂蛋白B(APOB)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
LAC003Hu71 | 載脂蛋白B(APOB)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
MAC003Hu24 | 載脂蛋白B(APOB)單克隆抗體 | WB; IHC; ICC; IP. |
MAC003Hu25 | 載脂蛋白B(APOB)單克隆抗體 | WB; IHC; ICC; IP. |
MAC003Hu23 | 載脂蛋白B(APOB)單克隆抗體 | WB; IHC; ICC; IP. |
MAC003Hu22 | 載脂蛋白B(APOB)單克隆抗體 | WB |
MAC003Hu21 | 載脂蛋白B(APOB)單克隆抗體 | WB |
MAC003Hu26 | 載脂蛋白B(APOB)單克隆抗體 | WB; IHC; ICC; IP. |
FAC003Hu06 | 抗載脂蛋白B(APOB)單克隆抗體 | Flow cytometry. |
FAC003Hu04 | 抗載脂蛋白B(APOB)單克隆抗體 | Flow cytometry. |
FAC003Hu02 | 抗載脂蛋白B(APOB)單克隆抗體 | Flow cytometry. |
FAC003Hu08 | 抗載脂蛋白B(APOB)單克隆抗體 | Flow cytometry. |
SEC003Hu | 載脂蛋白B(APOB)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
HEC003Hu | 載脂蛋白B(APOB)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
AEC003Hu | 抗載脂蛋白B抗體(Anti-APOB)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
SCC003Hu | 載脂蛋白B(APOB)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMC003Hu | 載脂蛋白B(APOB)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Journal of Lipid Research | Group 1B phospholipase A2 deficiency protects against diet-induced hyperlipidemia in mice [Jlr: M019463] |
J Clin Endocrinol Metab.? | Elevated retinol binding protein 4 induces apolipoprotein B production and associates with hypertriglyceridemia [Pubmed:25781360] |
Biochim Biophys Acta | Culturing of HepG2 cells with human serum improve their functionality and suitability in studies of lipid metabolism [PubMed: 26515253] |
Am J Cardiovasc Dis | Hypoascorbemia induces atherosclerosis and vascular deposition of lipoprotein (a) in transgenic mice [PubMed: 26064792] |
The Journal of Biological Chemistry | Proprotein convertase subtilisin/Kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of LDL receptor degradation [Pubmed:27284008] |
United States Patent Application | COMPOSITIONS AND METHODS FOR EFFICACIOUS AND SAFE DELIVERY OF SIRNA USING SPECIFIC CHITOSAN-BASED NANOCOMPLEXES [y2016:0152988.html] |
alcohol and alcoholism | Hops (Humulus lupulus) Content in Beer Modulates Effects of Beer on the Liver After Acute Ingestion in Female Mice. [pubmed:27659607] |
Frontiers in Physiology | Change in the Lipid Transport Capacity of the Liver and Blood during Reproduction in Rats [pubmed:28798692] |
Food?Research International | Wild Lonicera caerulea berry polyphenol extract reduces cholesterol accumulation and enhances antioxidant capacity in vitro and in vivo [Pubmed:29580541] |
Journal of The Science of Food and Agriculture | Consumption of orange fermented beverage improves antioxidant status and reduces peroxidation lipid and inflammatory markers in healthy humans [Pubmed:29124773] |
European?Journal of Pharmacology | The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and concentration in?… [Pubmed: 30768981] |
Nature Communications | Hepatic HuR modulates lipid homeostasis in response to high-fat diet [Pubmed: 32546794] |
Study of in Vivo Serum Lipid Regulation with Ulmus macrocarpa Hance Extract in Rats [] | |
Nat Commun | GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity [34853313] |